On January 12, 2023, the Board of Directors of Cyteir Therapeutics, Inc. (the Company) approved a workforce reduction by approximately 70% of the Company's workforce, to better align with current research and development priorities and scope of business. The Company expects to substantially complete the reduction in its workforce in the first quarter of 2023. Following the changes, the Company expects to have 15 or fewer full-time employees.

The Company estimates that, in connection with these changes, it will incur aggregate charges of approximately $2.5 million to $3 million, all of which are anticipated to result in future cash expenditures, primarily for one-time employee severance and benefit costs, the majority of which are expected to be incurred in the first quarter of 2023.